Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease in Preterm Infants With Respiratory Distress Syndrome: A Multicenter Clinical Trial
Authors:
- 1 October 1997
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 100 (4) , e3
Abstract
Objectives. To study whether early postnatal (Materials and Methods. A multicenter randomized, double-blind clinical trial was undertaken on 262 (saline placebo, 130; dexamethasone, 132) preterm infants (4, and 6-keto prostaglandin F1α. All infants were observed for possible side effects, including hypertension, hyperglycemia, sepsis, intraventricular hemorrhage, retinopathy of prematurity, cardiomyopathy, and alterations in calcium homeostasis, protein metabolism, and somatic growth. Results. Infants in the dexamethasone group had a significantly lower incidence of chronic lung disease than infants in the placebo group either judged at 28 postnatal days (21/132 vs 40/130) or at 36 postconceptional weeks (20/132 vs 37/130). More infants in the dexamethasone group than in the placebo group were extubated during the study. There was no difference between the groups in mortality (39/130 vs 44/132); however, a higher proportion of infants in the dexamethasone group died in the late study period, probably attributable to infection or sepsis. There was no difference between the groups in duration of oxygen therapy and hospitalization. Early postnatal use of dexamethasone was associated with a significant decrease in tracheal aspirate cell counts, protein, leukotriene B4, and 6-keto prostaglandin F1α, suggesting a suppression of pulmonary inflammatory response. Significantly more infants in the dexamethasone group than in the placebo group had either bacteremia or clinical sepsis (43/132 vs 27/130). Other immediate, but transient, side effects observed in the dexamethasone group are: an increase in blood glucose and blood pressure, cardiac hypertrophy, hyperparathyroidism, and a transient delay in the rate of growth. Conclusions. In preterm infants with severe respiratory distress syndrome requiring assisted ventilation shortly after birth, early postnatal dexamethasone therapy reduces the incidence of chronic lung disease, probably on the basis of decreasing the pulmonary inflammatory process during the early neonatal period. Infection or sepsis is the major side effect that may affect the immediate outcome. Other observable side effects are transient. In view of the significant side effects and the lack of overall improvement in outcome and mortality, and the lack of long term follow-up data, the routine use of early dexamethasone therapy is not yet recommended.Keywords
This publication has 36 references indexed in Scilit:
- Adrenocortical function in the very low birth weight infant: Improved testing sensitivity and association with neonatal outcomeThe Journal of Pediatrics, 1996
- Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infantThe Journal of Pediatrics, 1995
- Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasiaThe Journal of Pediatrics, 1994
- Influence of perinatal conditions on C-reactive protein productionThe Journal of Pediatrics, 1992
- A Controlled Trial of Dexamethasone in Preterm Infants at High Risk for Bronchopulmonary DysplasiaNew England Journal of Medicine, 1989
- A randomized, placebo-controlled trial of effects of dexamethasone on hypothalamic-pituitary-adrenal axis in preterm infantsThe Journal of Pediatrics, 1988
- Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacinThe Journal of Pediatrics, 1987
- Glucocorticoids alter the sensitivity of the lamb ductus arteriosus to prostaglandin E2The Journal of Pediatrics, 1981
- Prenatal administration of betamethasone for prevention of patent ductus arteriosusThe Journal of Pediatrics, 1981
- Glucocorticoid prophylaxis for respiratory distress syndrome: A review of potential toxicityThe Journal of Pediatrics, 1975